Lv5
830 积分 2023-11-16 加入
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
14小时前
已完结
REAL-WORLD OUTCOMES FOLLOWING BIOLOGIC INITIATION IN US PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
16小时前
已完结
Head-to-Head Effectiveness Comparison of Biological Therapies in Patients With Mixed Eosinophilic and Allergic Severe Asthma
18小时前
已完结
Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study
19小时前
已完结
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
19小时前
已完结
Exploring the Effects of Omalizumab in Allergic Asthma
19小时前
已完结
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study
1天前
已完结
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
1天前
已完结
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
1天前
已完结
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
1天前
已完结
皖公网安备34019202002308
